| Literature DB >> 11561679 |
R T Zon1, J McClean, D Helman, R Ansari, J Picus, A Sandler, S D Williams, P J Loehrer.
Abstract
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11561679 DOI： 10.1023/a:1010620601431
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850